Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IPN60340 + azacitidine + venetoclax
- Development stage
- Unknown
- Lead developer
- Ipsen
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Administration
- Oral, Intravenous, Subcutaneous
01
Overview
IPN60340 + azacitidine + venetoclax is an investigational triplet combination therapy being developed by Ipsen for the treatment of newly diagnosed acute myeloid leukemia (AML) in patients who are ineligible for intensive chemotherapy. The regimen consists of **IPN60340**, a first-in-class molecular glue degrader of **GSPT1** (G1 to S phase transition 1), combined with the standard-of-care agents **azacitidine** (a hypomethylating agent) and **venetoclax** (a BCL-2 inhibitor). IPN60340, which originated from a collaboration between Ipsen and Plexium, induces the proteasomal degradation of GSPT1, a translation termination factor essential for the survival of AML cells. By combining this novel mechanism with DNA methyltransferase inhibition and BCL-2-mediated apoptosis induction, the triplet aims to overcome resistance and improve remission rates compared to the doublet of azacitidine and venetoclax. The combination is currently being evaluated in a global Phase 2b/3 randomized, double-blind study (NCT06340100).
- Other names
- IPN60340 + AZA + VEN
02
Targets
BCL-2 (BCL-2 family)BTN3A (Butyrophilin subfamily 3 member A)
Beyond the preview
Go deeper on IPN60340 + azacitidine + venetoclax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IPN60340 + azacitidine + venetoclax.